跳至主要内容
临床试验/NCT00812682
NCT00812682已完成不适用

Physician and Patient Perception of Adjustable Maintenance Dosing of Symbicort Turbuhaler

AstraZeneca0 个研究点目标入组 217 人开始时间: 2006年9月最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
AstraZeneca
入组人数
217
主要终点
Patient satisfaction with the adjustable maintenance dosing schedule

研究概览

简要总结

This study will evaluate the perception of the physicians and the patients about the approved adjustable dosing of Symbicort® 160/4,5. Symbicort maintenance dose will be adjusted up and down within the approved dose range of 1x2 - 4x2 inhalations per day, to the level of asthma symptoms. Patients and physicians perception of this new dosing schedule will be evaluated by means of questionnaires completion and direct questioning.

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Prospective

入排标准

年龄范围
12 Years 至 —(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Minimum of 6 months history of asthma and treatment with an inhaled corticosteroids for at least 3 months prior to visit 1 and/or a history of short term variation in airway function and asthma symptoms responding promptly to convent
  • Patients where use of a combination (inhaled corticosteroid and long acting beta2-agonist is appropriate, i.e. not controlled on inhaled corticosteroids alone).

排除标准

  • Asthma exacerbation requiring oral corticosteroid treatment in the four weeks prior to visit 1
  • Upper Respiratory Tract Infection in the previous four weeks
  • Severe cardiovascular disease or other significant concomitant disease, which may interfere with the conduct of the study.
  • Women enrolled in the trial should not be planning pregnancy and should be taking adequate contraceptive measures where appropriate.
  • Previous enrollment in a clinical study
  • Known or suspected hypersensitivity to budesonide, formoterol or inhaled lactose

结局指标

主要结局

Patient satisfaction with the adjustable maintenance dosing schedule

时间窗: Throughout the study

Physicians' satisfaction with the adjustable maintenance dosing schedule

时间窗: Throughout the study

次要结局

未报告次要终点

研究者

发起方
AstraZeneca
申办方类型
Industry

相似试验